PB-718 / PegBio - LARVOL DELTA

A Phase 1b/2a Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of PB-718, a GLP-1R/GCGR Dual Agonist in Subjects with Obesity (ADA 2024) - P1/2 | "Introduction: PB-718 is a fixed dose combination of PB-119 (GLP-1 receptor agonist) and PB-722 (glucagon receptor agonist in clinical development. PB-718 was safe, had predicted PK profile, and led to greater reductions in BW, HbA1c, blood lipids, uric acid, liver fat content and visceral fat mass. These data highlight the potential for PB-718 to provide additional benefit, and support the development of PB-718 as a promising treatment for obesity and NASH."

Clinical • P1/2 data • PK/PD data • Diabetes • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Obesity

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PB-718 Injection in Chinese Obese Subjects. (clinicaltrials.gov) - P1/2 | N=36 | Completed | Sponsor: PegBio Co., Ltd. | Recruiting ➔ Completed

Trial completion • Genetic Disorders • Obesity

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PB-718 Injection in Chinese Obese Subjects. (clinicaltrials.gov) - P1/2 | N=36 | Recruiting | Sponsor: PegBio Co., Ltd.

New P1/2 trial • Genetic Disorders • Obesity

A Phase 1, Double-blind, Randomized, Placebo-controlled, Single- and Multiple-dose Escalating Study (clinicaltrials.gov) - P1 | N=82 | Completed | Sponsor: PegBio Co., Ltd. | Recruiting ➔ Completed

Trial completion

A Phase 1, Double-blind, Randomized, Placebo-controlled, Single- and Multiple-dose Escalating Study (clinicaltrials.gov) - P1; N=80; Recruiting; Sponsor: PegBio Co., Ltd.; Initiation date: Aug 2019 ➔ Jul 2020

Clinical • Trial initiation date

A Phase 1, Double-blind, Randomized, Placebo-controlled, Single- and Multiple-dose Escalating Study (clinicaltrials.gov) - P1; N=80; Recruiting; Sponsor: PegBio Co., Ltd.

Clinical • New P1 trial